October 5, 2020
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session
Breda, the Netherlands / Ghent, Belgium
argenx (Euronext & Nasdaq: ARGX) today announced the presentation of new data from the pivotal Phase 3 ADAPT trial evaluating efgartigimod for the treatment of patients with generalized myasthenia gravis (gMG).
More Press Releases
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020
October 6, 2020
argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships